The global peptide therapeutics market size was estimated to be US$ 41.5 billion in 2022 and is expected to reach US$ 70 billion by 2032 at a CAGR of 5.4%.
Peptide therapeutics are advanced pharmaceutical with physiological and functional properties ranging between the biopharmaceuticals and small molecules. These are highly selective, efficacious, well tolerated and safe for consumption. Increasing investment in the development of advanced therapeutics for treatment of type 2 diabetes, cancer, and metabolic disease are the key growth contributors of peptide therapeutics market.
The pharmaceutical manufacturers are continuously focused on development of new and advanced drugs as an alternative to conventional drugs and therapies used for treatment of cancer, infectious diseases, diabetes and disorders of gastrointestinal tract.
The evolution of peptide therapeutics manufacturing process is another factor responsible for the development of peptide during the forecast period. The global peptide therapeutics market is anticipated to witness prominent growth in coming years.
North America contributed the largest share to the global peptide therapeutics market in 2019 and is anticipated to be a dominating geography during the forecast period owing to increasing investment in research and development activities focused on development for production of new peptide therapeutic.
Constant growth of cancer patients, increasing number of patients suffering from cardiovascular and lifestyle disorders and rising federal investment for development of advanced therapeutics is anticipated to drive the North America peptide therapeutic market in coming years.
Europe is anticipated to contribute a prominent share to the global market during the forecast period owing to the presence of key pharmaceutical manufacturers in the U.K., Germany, France and other European countries. Asia Pacific is expected to witness significant growth in coming owing to the expansion of pharmaceutical research and manufacturing industry in India, China, Japan, South Korea, and Singapore.
The report titled “Peptide Therapeutics Market - Global Market Share, Trends, Analysis and Forecasts, 2023-2032” wherein 2021 is historic period, 2022 is the base year, and 2023 to 2032 is forecast period. Additionally, the study takes into consideration the competitive landscape, wherein the report would provide company overview and market outlook for leading players in the global peptide therapeutics market.
Furthermore, the report would reflect the key developments, global & regional sales network, business strategies, research & development activities, employee strength, and key executive, for all the major players operating in the market. For instance, GlaxoSmithKline plc reported revenues of USD 41,974.1 million in 2019 and the product segment analysis of the company indicates that Pharmaceuticals business segment of the company dominated revenue in 2019 with North America being the largest revenue contributing geography under the Pharmaceutical business segment.
The global peptide therapeutics market is segmented based on product type, technology, route of administration, applications, and geography. Based on product type, the global peptide therapeutics market is segmented into generic peptide therapeutics and innovative peptide therapeutics. Based on technology, the global peptide therapeutics market is segmented into solid phase peptide synthesis (SPPS), liquid phase peptide synthesis (LPPS), and hybrid technology. Based on route of administration, the global peptide therapeutics market is segmented into parenteral route, oral route, pulmonary, mucosal, and others. Based on applications, the global peptide therapeutics market is segmented into cancer, metabolic disorders, cardiovascular disorder, respiratory disorders, gastrointestinal tract disorders (GIT), anti-infection, dermatology, central nervous system (CNS) disorders, renal disorders, and others. Based on geography, the global peptide therapeutics market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America.
The research provides in-depth analysis of prominent players holding majority share of the global market with a focus on all operating business segment, and would identify the segment of the company focusing on peptide therapeutics. Further, market share of prominent companies in the global peptide therapeutics market would also be estimated.
For instance, GlaxoSmithKline plc operates through three business segments namely Pharmaceuticals, Vaccines, and Consumer Health. The peptide therapeutics are delivered under Pharmaceuticals business segment of the company with revenue contribution of US$ 21,860.0 million in 2019.
The study takes into consideration the key competitive information such as business strategy, product portfolio, key development, SWOT analysis, and research and development focus of all the peptide therapeutic companies. The global peptide therapeutics market study would take into consideration the participants engaged throughout the value chain and supply chain of the market, along with their contribution.
Product portfolio would focus on all the products under the peptide therapeutics business segment of the company. Similarly, the recent development section would focus on the latest developments of company such as strategic alliances and partnerships, merger and acquisition, new product launched and geographic expansion in the global peptide therapeutics market.
Major players active in the global peptide therapeutics market include Amgen, Inc., AstraZeneca PLC, Bristol-Myers Squibb (BMS), Eli Lilly and Company, GlaxoSmithKline plc (GSK), Lonza Inc., Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceuticals Industries Ltd.
By Product Type
- generic peptide therapeutics
- innovative peptide therapeutics
- solid phase peptide synthesis (SPPS)
- liquid phase peptide synthesis (LPPS)
- hybrid technology
By Route of administration
- parenteral route
- oral route
- metabolic disorders
- cardiovascular disorder
- respiratory disorders
- gastrointestinal tract disorders (GIT)
- central nervous system (CNS) disorders
- renal disorders
- North America
- South America
- Middle East and Africa